NASP Controls Histone Turnover Behind PARP Resistance
The emergence of poly(ADP-ribose) polymerase inhibitors (PARPi) as a transformative therapy for homologous recombination-deficient tumors has significantly altered the landscape of cancer treatment. These drugs...